Aura Biosciences to Join Jefferies Global Healthcare Conference

BOSTON, May 30, 2024 – Aura Biosciences, Inc. (NASDAQ: AURA), a biotechnology firm in the clinical stage, revealed that its CEO, Elisabet de los Pinos, PhD, will be presenting at the Jefferies Global Healthcare Conference. The session is scheduled for Thursday, June 6, 2024, at 12:30 p.m. ET. 

For those unable to attend in person, a live webcast will be accessible via the "Investors & Media" page under the “Events & Presentations” section of the company’s website. The webcast will remain available for replay for 90 days after the event.

Aura Biosciences Overview

Aura Biosciences is dedicated to creating precision immunotherapies aimed at treating solid tumors while preserving the functionality of the affected organs. Its leading candidate, bel-sar, is currently in the latter stages of clinical trials for treating primary uveal melanoma and other ocular cancer conditions. Additionally, bel-sar is in the preliminary phases of clinical development for bladder cancer.

Bel-sar's Potential

Bel-sar is being assessed for its safety and effectiveness as a potential vision-sparing treatment in an ongoing global Phase 3 CoMpass trial. This trial focuses on the first-line treatment of adult patients with early-stage uveal melanoma. Beyond ocular cancers, bel-sar is also being tested for its effectiveness against other solid tumors, including those in the bladder.

Aura Biosciences’ Mission

Aura Biosciences is headquartered in Boston, MA, and is committed to developing therapies that not only treat cancer but also aim to preserve the organs affected by the disease, thereby improving patient outcomes. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!